A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

Inclusion Criteria: * Voluntarily participate in this study, sign the informed consent form, and have good compliance; * Eastern Cooperative Oncology Group performance status (ECOG PS) score: 0-1; expected survival \>6 months; * Histologically or cytologically confirmed HER2-positive invasive breast cancer; * Hormone receptor (HR) status confirmed; * Clinical stage at diagnosis: T2-4 with any N, M0, or any T with N1-3, M0; * Agree to undergo breast cancer resection if meeting surgical criteria after neoadjuvant therapy; * Major organ function is adequate, meeting specific criteria; * Must agree to use contraception during the study and for 6 months after study completion; female patients must have a negative serum pregnancy test within 7 days before enrollment and must not be lactating; male subjects must agree to use contraception during the study and for 6 months after study completion Exclusion Criteria: * Stage IV metastatic breast cancer or other cases judged by the investigator as unsuitable for radical surgical resection after neoadjuvant therapy; * Bilateral breast cancer or inflammatory breast cancer; * History of invasive breast cancer or ductal carcinoma in situ; * Prior anti-tumor therapy for breast cancer, including chemotherapy, endocrine therapy, targeted therapy, radiotherapy, surgery, etc.; * Comorbidities and medical history: * Other malignancies within 5 years or currently; * Adverse reactions from prior treatment not recovered to CTCAE v5.0 grade ≤1; * Major surgery, significant traumatic injury within 4 weeks before first dose, or anticipated major surgery during the study, or unhealed wounds/fractures; * Conditions affecting intravenous injection or blood sampling; * Congenital bleeding or coagulation disorders, or bleeding/coagulation disorders within 28 days before study treatment, or use of aspirin \>325 mg/day (maximum antiplatelet dose), dipyridamole, ticlopidine, clopidogrel, or cilostazol within 7 days before study treatment; * Arterial/deep venous thrombotic events within 6 months before first dose, e.g., cerebrovascular accident, deep vein thrombosis, pulmonary embolism; * Poorly controlled blood pressure (systolic ≥150 mmHg or diastolic ≥100 mmHg); * Significant cardiovascular disease, including； * Uncontrolled ≥CTCAE grade 2 infection within 14 days before study treatment; * History of interstitial lung disease/pneumonitis (non-infectious) requiring steroid treatment, current interstitial lung disease/pneumonitis, or suspected interstitial lung disease/pneumonitis on screening imaging that cannot be ruled out; * Tumor-related symptoms and treatment: * Prior excisional biopsy of primary tumor and/or axillary lymph nodes or sentinel lymph node biopsy before study treatment; * Surgery, chemotherapy, radiotherapy, or other anti-tumor therapy within 3 weeks before study treatment (washout period calculated from last treatment); * Prior taxane or carboplatin therapy for any malignancy; * Treatment with National Medical Products Administration-approved traditional Chinese medicine with clear anti-tumor indications within 2 weeks before study treatment. * Study treatment-related: * Severe hypersensitivity to monoclonal antibodies; * Uncontrolled active autoimmune disease within 2 weeks before study treatment; * Allergy to any study drug or its components/excipients; * Live vaccination within 28 days before study treatment, including measles, mumps, rubella, varicella, yellow fever, seasonal flu, Influenza A virus subtype (H1N1) flu, rabies, Bacille Calmette-Guerin vaccine (BCG), and typhoid vaccines. * Any condition judged by the investigator to jeopardize subject safety or study completion.